| Price | $3.36 |
| Year Range | $1.08 – $6.38 |
| Market Cap | $16M |
| Industry | Biotechnology |
What Is Cyclerion Therapeutics’s AI Stock Analysis?
Cyclerion Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Cyclerion Therapeutics’s momentum in near-real time.
Cyclerion Therapeutics (CYCN) has an AltIndex AI Score of 49/100, currently a Hold signal. The AI Score distills Cyclerion Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Cyclerion Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Cyclerion Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving CYCN’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. However, compared to the same quarter last year, there is a decrease of 100.00%, which may be a cause for concern. Net income for the last quarter was $-1.8M. This is an increase of -44.76% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 441.67%, which may be a cause for concern. Ebitda for the last quarter was $-1.8M. This is an increase of -44.76% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 441.67%, which may be a cause for concern.
See Cyclerion Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $3.36. This represents a decrease of 20.94% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 33.33%, suggesting a positive long-term trend. The trend is neutral. The current SMA10 of $3.36 is equal to the previous SMA10, indicating no significant change in the trend. The RSI is 12.1, indicating a potentially oversold (bullish) condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Cyclerion Therapeutics is neutral. Cyclerion Therapeutics has an estimate of 2,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Cyclerion Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Cyclerion Therapeutics has 350 followers on their Twitter page. The number of followers is down by -1% in the last couple of months, indicating a loss in interest in the company.
Track Cyclerion Therapeutics’s market sentiment.
Frequently Asked Questions: Cyclerion Therapeutics AI Stock Analysis
Cyclerion Therapeutics's AltIndex AI Score is 49/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Cyclerion Therapeutics a Hold (49/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Cyclerion Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the CYCN AI Score or sign up to read the full thesis.
